Nivata Wealth

STAR · What Changed

What Changed at
Strides Pharma Science Limited?

See reported financial changes and material NSE disclosures for Strides Pharma Science Limited.

My CompaniesSaved on this device. No account needed.
Follow a company to build your personal change feed.

Latest company changes

Strides Pharma Science Limited

Start with what changed, then open the supporting financial and operating detail only when you need it.

STAR · Consolidated

Strides Pharma Science Limited

Q2 FY27 Results

Q2 FY27

Latest reported changes

What Changed

Worth reviewing Neutral / mixed NSE disclosure · 29 Oct 2026
Governance

The company disclosed the company filed a governance update concerning directors, KMP, senior management, auditors or its RTA.
View NSE filing ↗
Worth reviewing Neutral / mixed NSE disclosure · 29 Oct 2026
Capital

The company allotted Securities Alteration Of Capital and Fund Ra.
View NSE filing ↗
Worth reviewing Neutral / mixed NSE disclosure · 29 Oct 2026
Management

The company appointed Biren Gabhawala as Non- Executive Independent Director of the company w.e.f. November 01, 2026. Appointment.
View NSE filing ↗

Showing 1–3 of 3 recorded updates from the past 90 days

Financial snapshot

Latest Reported Financials

Available reported figures from the latest period.

Revenue from operations₹1,429.73 Cr
Q2 FY27
Total income₹1,433.82 Cr
Q2 FY27
Profit after tax₹134.12 Cr
Q2 FY27
EPS₹14.19
Q2 FY27
Profit before tax₹150.44 Cr
Q2 FY27
Supporting financial context

Margins and Supporting Figures

Only reported or directly calculated figures that are available for this company.

Supporting financial contextProfitability
PAT margin9.38%
Profit before tax₹150.44 Cr
Supporting financial contextSupporting reported figures
Finance cost₹46.54 Cr
Depreciation₹57.22 Cr
Tax₹16.32 Cr
Today

Today on Nivata

Loading today’s changes…
— meaningful changes— companies

Checking the latest tracked company developments…